A high creatinine that is not kidney damage: drugs and supplements that move the number

The reason serum creatinine works as a kidney marker is that healthy kidneys clear it and failing kidneys do not, so the blood level rises as filtration falls. That is true, and it is incomplete. Creatinine gets into urine by two routes. Most of it is filtered at the glomerulus. A meaningful share is pushed across the tubule by active transporters, a process called tubular secretion.

That second route is the one that can be interfered with. If a drug blocks the transporters, creatinine backs up in the blood while glomerular filtration carries on exactly as before. The lab sees a higher creatinine, the equation converts it into a lower eGFR, and the report describes a decline in kidney function that has not happened.

Trimethoprim is half of co-trimoxazole, sold in the United States as Bactrim or Septra, a frequently prescribed antibiotic worldwide, used to treat and to prevent urinary tract and Pneumocystis infections. A 2011 review in Nephron Clinical Practice states the effect precisely: the trimethoprim component, even at recommended doses, inhibits tubular creatinine secretion, producing a rapid but ultimately reversible increase in serum creatinine independent of any change in glomerular filtration rate, and a falsely low estimated GFR when creatinine-based equations are used.

The same review draws a distinction worth holding onto. The other half of the combination, sulfamethoxazole, appears to be genuinely nephrotoxic at high doses or at doses inappropriately adjusted for GFR. So co-trimoxazole can raise creatinine for two entirely different reasons, one an artifact of measurement and one real injury, and the dose is part of telling them apart.

A 2022 retrospective study of 111 hospitalized patients taking oral trimethoprim-sulfamethoxazole found the daily trimethoprim dose was the common variable affecting the change in creatinine, sodium and potassium, and that hyponatremia and hyperkalemia patterns separated at a trimethoprim dose above 160 mg per day (p = 0.005 and p = 0.008). The electrolyte effects travel with the creatinine effect, which is a reason not to dismiss the whole picture as harmless bookkeeping.

Cobicistat is a pharmacoenhancer, given to raise blood levels of other drugs rather than to treat anything itself. It is known to increase serum creatinine, and a 2014 study in Kidney International set out to find the mechanism. Its opening statement is the general principle: many xenobiotics including cobicistat increase serum creatinine by inhibiting its renal active tubular secretion without affecting the glomerular filtration rate.

The study identified the organic anion transporter OAT2 as a creatinine transporter whose specific activity at physiologic creatinine concentrations was more than twice that of the organic cation transporters OCT2 and OCT3, which the authors say challenges the traditional view that creatinine is handled solely by a cationic pathway. Cobicistat itself acts elsewhere. Its largest effect was on the apical transporter MATE1, with a 50% inhibition constant of 0.99 micromolar for creatinine transport, and the authors conclude that the raised creatinine in patients taking it is likely the result of OCT2 transport driving intracellular accumulation plus MATE1 inhibition. The practical point for a reader is narrower: this is a documented, mechanistically explained way for a creatinine result to move without kidneys changing.

Creatine monohydrate is among the most used supplements in strength training, and the standard warning is that it raises creatinine and will make your kidney test look worse. The mechanism offered is that creatine turns over into creatinine, so more creatine in means more creatinine out, with no kidney injury involved.

A 2025 systematic review and meta-analysis in BMC Nephrology tested it. It pooled 177 participants taking creatine against 263 controls and found a statistically significant increase in serum creatinine: a mean difference of 0.07, 95% CI 0.01 to 0.12, p = 0.03. We are not converting that into mg/dL, because we cannot establish the unit. The review names it as micromoles per liter once, in the abstract, and reports the same mean difference with no unit at all in its results section, where it also gives the pooled study count as fourteen rather than the twelve its abstract states. Take the direction from this paper and not the size.

The honest summary is that both halves of the popular claim need trimming. A rise in creatinine on creatine is real and statistically significant, and the review cannot tell you how big it is. Kidney function held in the trials that measured it, and those trials were few, small, and did not include anyone with kidney disease. Neither half is a license to ignore a genuinely abnormal result.

Three features separate them, and none require a specialist. Timing: a secretion effect appears within days of starting the drug rather than drifting over months. Reversibility: the 2011 review describes the trimethoprim rise as ultimately reversible, so the value returns after the course ends. Company: real kidney injury usually brings other findings with it, and albuminuria in particular is a separate signal that a transporter effect does not produce. A second estimate built on a different molecule, cystatin C, exists for exactly this kind of doubt. KDIGO's 2024 chronic kidney disease guideline lists a medication that decreases tubular secretion among its indications for measuring cystatin C, and says a cystatin C estimate may be appropriate when the medication affects only creatinine and there is no comorbid illness.

What none of this supports is deciding for yourself that a high creatinine is your supplement or your antibiotic. It is a question to put to whoever ordered the test, with the medication list and the dates in hand, and it is a specific enough question to get a specific answer.

Bring the date you started any new medication or supplement, the dose, and the creatinine values before and after. If the rise lines up with a start date and nothing else changed, say so plainly. If the value has drifted over months with no new drug, that is the other conversation, and a urine albumin-to-creatinine ratio is usually the next test in it. What a low eGFR actually means is the place to start on that one.